AI Based Workflow for Single Cell Analysis
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.
RPGR Gene Therapy for Retinitis Pigmentosa
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.
Mini-Bioreactor for Enhanced Organoid Culture
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.
Biodegradable Tissue Scaffold for Multi-Tissue Transplantation
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.
Targeted Disruption of Rpe65 Gene for Retinal Disease Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.
Snapwell Shipping Container for Live Cell Cultures
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.
Innovative Gene Therapy for Retinal Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.